JP2014515762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515762A5 JP2014515762A5 JP2014509281A JP2014509281A JP2014515762A5 JP 2014515762 A5 JP2014515762 A5 JP 2014515762A5 JP 2014509281 A JP2014509281 A JP 2014509281A JP 2014509281 A JP2014509281 A JP 2014509281A JP 2014515762 A5 JP2014515762 A5 JP 2014515762A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- occurrence
- independently
- amino acid
- carrier peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000562 conjugate Substances 0.000 claims description 118
- 235000001014 amino acid Nutrition 0.000 claims description 74
- 229940024606 amino acid Drugs 0.000 claims description 74
- 150000001413 amino acids Chemical class 0.000 claims description 70
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 30
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 239000004475 Arginine Substances 0.000 claims description 18
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 239000004471 Glycine Substances 0.000 claims description 12
- 230000002209 hydrophobic effect Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 12
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- -1 glycine amino acid Chemical class 0.000 claims description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 244000007835 Cyamopsis tetragonoloba Species 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 150000001484 arginines Chemical class 0.000 claims description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 208000018360 neuromuscular disease Diseases 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000000863 peptide conjugate Substances 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical group NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000000747 amidyl group Chemical group [H][N-]* 0.000 claims description 2
- 229960002684 aminocaproic acid Drugs 0.000 claims description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 229940000635 beta-alanine Drugs 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 230000027455 binding Effects 0.000 claims description 2
- 150000001721 carbon Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000001268 conjugating effect Effects 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229940009976 deoxycholate Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 235000004554 glutamine Nutrition 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 150000004713 phosphodiesters Chemical class 0.000 claims description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/101,942 US20110269665A1 (en) | 2009-06-26 | 2011-05-05 | Compound and method for treating myotonic dystrophy |
| US13/101,942 | 2011-05-05 | ||
| US13/107,528 US9238042B2 (en) | 2010-05-13 | 2011-05-13 | Antisense modulation of interleukins 17 and 23 signaling |
| US13/107,528 | 2011-05-13 | ||
| PCT/US2011/061282 WO2012150960A1 (en) | 2011-05-05 | 2011-11-17 | Peptide oligonucleotide conjugates |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016151179A Division JP2016185991A (ja) | 2011-05-05 | 2016-08-01 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2018108772A Division JP2018135396A (ja) | 2011-05-05 | 2018-06-06 | ペプチドオリゴヌクレオチドコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515762A JP2014515762A (ja) | 2014-07-03 |
| JP2014515762A5 true JP2014515762A5 (enExample) | 2015-01-29 |
| JP6478632B2 JP6478632B2 (ja) | 2019-03-06 |
Family
ID=45218873
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509281A Active JP6478632B2 (ja) | 2011-05-05 | 2011-11-17 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2016151179A Pending JP2016185991A (ja) | 2011-05-05 | 2016-08-01 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2018108772A Withdrawn JP2018135396A (ja) | 2011-05-05 | 2018-06-06 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2020070566A Active JP6884250B2 (ja) | 2011-05-05 | 2020-04-09 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2021080358A Pending JP2021113232A (ja) | 2011-05-05 | 2021-05-11 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2024014898A Pending JP2024032974A (ja) | 2011-05-05 | 2024-02-02 | ペプチドオリゴヌクレオチドコンジュゲート |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016151179A Pending JP2016185991A (ja) | 2011-05-05 | 2016-08-01 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2018108772A Withdrawn JP2018135396A (ja) | 2011-05-05 | 2018-06-06 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2020070566A Active JP6884250B2 (ja) | 2011-05-05 | 2020-04-09 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2021080358A Pending JP2021113232A (ja) | 2011-05-05 | 2021-05-11 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2024014898A Pending JP2024032974A (ja) | 2011-05-05 | 2024-02-02 | ペプチドオリゴヌクレオチドコンジュゲート |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2704749A1 (enExample) |
| JP (6) | JP6478632B2 (enExample) |
| KR (3) | KR102339196B1 (enExample) |
| CN (2) | CN107693797B (enExample) |
| AU (6) | AU2011367230B2 (enExample) |
| CA (2) | CA2834128A1 (enExample) |
| IL (2) | IL273838B (enExample) |
| WO (1) | WO2012150960A1 (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627917T3 (es) | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| WO2006086667A2 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| JP6047270B2 (ja) | 2006-08-11 | 2016-12-21 | バイオマリン テクノロジーズ ベー．フェー． | Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段 |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| NZ584793A (en) | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| EP3133160B1 (en) | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| HUE040445T2 (hu) | 2009-11-12 | 2019-03-28 | Univ Western Australia | Antiszensz molekulák és eljárások betegségek kezelésére |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| KR20140097398A (ko) | 2011-11-18 | 2014-08-06 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| ES2727481T3 (es) | 2011-11-30 | 2019-10-16 | Sarepta Therapeutics Inc | Inclusión inducida de exón en atrofia muscular espinal |
| WO2013082548A1 (en) | 2011-11-30 | 2013-06-06 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
| WO2013086444A2 (en) | 2011-12-08 | 2013-06-13 | Sarepta Therapeutics, Inc. | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna |
| CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| PT2841578T (pt) | 2012-04-23 | 2017-08-10 | Biomarin Tech Bv | Resumo |
| CN106414739A (zh) | 2012-12-20 | 2017-02-15 | 萨雷普塔医疗公司 | 用于治疗肌营养不良症的改良的外显子跳跃组合物 |
| WO2014113540A1 (en) | 2013-01-16 | 2014-07-24 | Iowa State University Research Foundation, Inc. | A deep intronic target for splicing correction on spinal muscular atrophy gene |
| EP3760720A1 (en) * | 2013-03-14 | 2021-01-06 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| US9217148B2 (en) * | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| HK1220154A1 (zh) | 2013-03-15 | 2017-04-28 | Sarepta Therapeutics, Inc. | 改进的用於治疗肌营养不良的组合物 |
| JP6477464B2 (ja) * | 2013-05-24 | 2019-03-06 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| AU2014317961B2 (en) | 2013-09-05 | 2020-07-30 | Murdoch University | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| EP3086776B1 (en) | 2013-12-24 | 2020-06-17 | Sentiss Pharma Private Limited | Topical brimonidine tartrate ophthalmic solution |
| BR112016020618B1 (pt) * | 2014-03-12 | 2023-04-04 | Nippon Shinyaku Co., Ltd. | Oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido |
| KR101661277B1 (ko) * | 2014-03-17 | 2016-09-30 | 제주광어주식회사 | 한 개의 뉴크레오타이드 염기 변화를 통한 약독화 바이러스성 출혈패혈증 바이러스 |
| US9790495B2 (en) | 2014-05-16 | 2017-10-17 | Oregon State University | Antisense antibacterial compounds and methods |
| CA2948568A1 (en) | 2014-05-19 | 2015-11-26 | David Greenberg | Antisense antibacterial compounds and methods |
| WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
| WO2016108930A2 (en) | 2014-12-31 | 2016-07-07 | Geller Bruce L | Antisense antibacterial compounds and methods |
| MX2017011004A (es) * | 2015-02-27 | 2018-02-09 | Sarepta Therapeutics Inc | Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida. |
| MA41795A (fr) * | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| KR102644053B1 (ko) | 2015-05-19 | 2024-03-06 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 펩티드 올리고뉴클레오티드 콘주게이트 |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| RS62930B1 (sr) * | 2015-08-05 | 2022-03-31 | Eisai R&D Man Co Ltd | Postupak za pripremu suštinski dijastereomerno čistog fosforodiamidatnog oligomera, fosforodiamidatni oligomer proizveden takvim postupkom i farmaceutska kompozicija koja sadrži fosforodiamidatni oligomer |
| WO2017040271A1 (en) | 2015-08-28 | 2017-03-09 | Sarepta Therapeutics, Inc. | Modified antisense oligomers for exon inclusion in spinal muscular atrophy |
| CN108350030B (zh) * | 2015-09-10 | 2022-12-13 | 汉阳大学校产学协力团 | 皮肤可渗透肽及其使用方法 |
| JP2018530560A (ja) | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス， インコーポレイテッド | デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法 |
| GB2545898B (en) * | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| AU2016379399B2 (en) | 2015-12-23 | 2022-12-08 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| US11142764B2 (en) | 2015-12-23 | 2021-10-12 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| US11060089B2 (en) * | 2016-04-18 | 2021-07-13 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| JP7042255B2 (ja) | 2016-04-29 | 2022-03-25 | サレプタ セラピューティクス， インコーポレイテッド | ヒトｌｍｎａを標的にするオリゴヌクレオチド類縁体 |
| CA3024153A1 (en) * | 2016-06-30 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| KR20190024977A (ko) * | 2016-06-30 | 2019-03-08 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 |
| NZ755416A (en) * | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| ES3051834T3 (en) * | 2016-12-19 | 2025-12-30 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| PT4122497T (pt) | 2016-12-19 | 2024-06-12 | Sarepta Therapeutics Inc | Conjugados oligoméricos de salto de exão para a distrofia muscular |
| WO2018150196A1 (en) | 2017-02-17 | 2018-08-23 | Oxford University Innovation Limited | Cell penetrating peptides modified by glycosylation |
| TW201919682A (zh) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Ｎｒｆ２路徑的新穎化合物 |
| WO2019060522A2 (en) | 2017-09-22 | 2019-03-28 | The Regents Of The University Of Colorado, A Body Corporate | OLIGONUCLEOTIDES THIOMORPHOLINO FOR THE TREATMENT OF MUSCLE DYSTROPHY |
| EA201991450A1 (ru) * | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| JP2020536060A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| EP3687519A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| JP2020536058A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| WO2019079386A1 (en) * | 2017-10-17 | 2019-04-25 | Sarepta Therapeutics, Inc. | CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION |
| US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| EP3765030A4 (en) | 2018-03-16 | 2022-01-26 | Sarepta Therapeutics, Inc. | CHIMERIC PEPTIDES FOR ANTISENSE ADMINISTRATION |
| WO2019209764A2 (en) * | 2018-04-26 | 2019-10-31 | Sarepta Therapeutics, Inc. | Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
| EP4219717A3 (en) | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| US20220251551A1 (en) * | 2018-06-13 | 2022-08-11 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| TW202449155A (zh) | 2018-07-27 | 2024-12-16 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| EP3829597A4 (en) * | 2018-07-30 | 2022-05-18 | Sarepta Therapeutics, Inc. | TRIMER PEPTIDES FOR ANTISENSE ADMINISTRATION |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| AU2019394177A1 (en) | 2018-12-07 | 2021-06-10 | Oxford University Innovation Limited | Linkers |
| BR112021011018A2 (pt) | 2018-12-13 | 2021-08-31 | Sarepta Therapeutics, Inc. | Conjugados de oligômero para exon skipping para distrofia muscular |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| WO2020214763A1 (en) | 2019-04-18 | 2020-10-22 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| CN110724180B (zh) * | 2019-10-17 | 2021-08-20 | 山东大学 | 一种抑制新生血管生成的多肽及其应用 |
| IL294271A (en) | 2019-12-26 | 2022-08-01 | Nippon Shinyaku Co Ltd | Antisense nucleic acid that induces skipping of exon 50 |
| IL295797A (en) | 2020-02-22 | 2022-10-01 | Japan Chem Res | Human transfer receptor binding peptide |
| AU2021225957A1 (en) | 2020-02-28 | 2022-09-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating SMN2 |
| PE20230237A1 (es) | 2020-02-28 | 2023-02-07 | Nippon Shinyaku Co Ltd | Acidos nucleicos antisentido que inducen la omision del exon 51 |
| WO2022061216A1 (en) * | 2020-09-21 | 2022-03-24 | Icahn School Of Medicine At Mount Sinai | Archaea l30 proteins as universal influenza virus therapeutics |
| WO2022113799A1 (ja) * | 2020-11-30 | 2022-06-02 | 国立大学法人新潟大学 | アンチセンス核酸及びその使用 |
| US20240327831A1 (en) | 2020-12-23 | 2024-10-03 | Sarepta Therapeutics, Inc. | Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy |
| CA3211038A1 (en) * | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| WO2022232478A1 (en) | 2021-04-30 | 2022-11-03 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
| JPWO2022270585A1 (enExample) | 2021-06-23 | 2022-12-29 | ||
| TW202317147A (zh) | 2021-07-08 | 2023-05-01 | 日商日本新藥股份有限公司 | 析出抑制劑 |
| TW202308664A (zh) | 2021-07-08 | 2023-03-01 | 日商日本新藥股份有限公司 | 腎毒性減輕劑 |
| US20240316093A1 (en) | 2021-07-08 | 2024-09-26 | Nippon Shinyaku Co., Ltd. | Nephrotoxicity reducing agent |
| WO2023026994A1 (ja) | 2021-08-21 | 2023-03-02 | 武田薬品工業株式会社 | ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート |
| US20240366775A1 (en) | 2021-08-24 | 2024-11-07 | Peptidream Inc. | Human transferrin receptor binding antibody-peptide conjugate |
| US20240425864A1 (en) | 2021-09-30 | 2024-12-26 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
| WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| EP4493693A1 (en) | 2022-03-17 | 2025-01-22 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| EP4590311A2 (en) | 2022-09-21 | 2025-07-30 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
| EP4612292A1 (en) | 2022-11-02 | 2025-09-10 | Sarepta Therapeutics, Inc. | Formulation of an antisense oligomer conjugate |
| WO2025085810A2 (en) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2528107B2 (ja) | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| AU659482B2 (en) | 1991-06-28 | 1995-05-18 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| EP0903408A3 (en) | 1992-08-21 | 2005-11-02 | Biogen, Inc. | Tat-derived transport polypeptide |
| JPH0915828A (ja) | 1995-07-03 | 1997-01-17 | Fuji Photo Film Co Ltd | 写真処理システム用ペーパーカッター |
| US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
| ES2210761T3 (es) | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| AU741546B2 (en) * | 1997-07-24 | 2001-12-06 | Perseptive Biosystems, Inc. | Conjugates of transporter peptides and nucleic acid analogs, and their use |
| DE19933492B4 (de) * | 1999-07-16 | 2008-01-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung |
| US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| DE60233137D1 (de) | 2001-02-16 | 2009-09-10 | Univ R | Transporter mit beabstandeten arginin-teilchen |
| US20030224353A1 (en) | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| AU2004235396B2 (en) | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| KR101032853B1 (ko) | 2003-08-05 | 2011-05-06 | 에이브이아이 바이오파마 인코포레이티드 | 웨스트 나일 바이러스 감염을 치료하기 위한 약학적 조성물 |
| US20050171044A1 (en) | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| CA2565685A1 (en) * | 2004-05-04 | 2005-12-15 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
| US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| ES2627917T3 (es) | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
| WO2006086667A2 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| PT2548560E (pt) | 2005-06-23 | 2015-09-22 | Isis Pharmaceuticals Inc | Composições e métodos de modulação da excisão-união de smn2 |
| AU2006287530A1 (en) | 2005-09-08 | 2007-03-15 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| WO2007030691A2 (en) | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| CA2644262C (en) | 2006-03-07 | 2016-01-05 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
| LT2735568T (lt) | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| JP6047270B2 (ja) | 2006-08-11 | 2016-12-21 | バイオマリン テクノロジーズ ベー．フェー． | Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段 |
| EP2066812A4 (en) | 2006-09-21 | 2010-04-28 | Univ Rochester | COMPOSITIONS AND METHODS RELATED TO PROTEIN SHIFT THERAPY FOR MYOTONE DYSTROPHY |
| JP5227803B2 (ja) | 2006-11-24 | 2013-07-03 | ハイクス ラボラトリーズ合同会社 | スピロキノン化合物及び医薬組成物 |
| WO2009005783A1 (en) * | 2007-06-28 | 2009-01-08 | Blanchette Rockefeller Neurosciences Institute | Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CA2691673A1 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| MX2010004955A (es) | 2007-11-15 | 2010-06-30 | Avi Biopharma Inc | Metodo de sintesis de oligomeros de morfolina. |
| EP2235175A4 (en) * | 2007-12-20 | 2012-04-25 | Angiochem Inc | POLYPEPTIDE NUCLEIC ACID CONJUGATES AND USES THEREOF |
| US20110130346A1 (en) * | 2008-05-30 | 2011-06-02 | Isis Innovation Limited | Peptide conjugates for delvery of biologically active compounds |
| EP3133160B1 (en) * | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| US20120149757A1 (en) | 2009-04-13 | 2012-06-14 | Krainer Adrian R | Compositions and methods for modulation of smn2 splicing |
| KR20220084437A (ko) | 2009-06-17 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법 |
| EP3023496B1 (en) * | 2010-05-13 | 2020-07-29 | Sarepta Therapeutics, Inc. | Compounds which modulate interleukins 17 and 23 signaling activity |
-
2011
- 2011-11-17 AU AU2011367230A patent/AU2011367230B2/en active Active
- 2011-11-17 WO PCT/US2011/061282 patent/WO2012150960A1/en not_active Ceased
- 2011-11-17 CN CN201710707423.0A patent/CN107693797B/zh active Active
- 2011-11-17 CA CA2834128A patent/CA2834128A1/en active Pending
- 2011-11-17 KR KR1020217007616A patent/KR102339196B1/ko active Active
- 2011-11-17 EP EP11793913.2A patent/EP2704749A1/en active Pending
- 2011-11-17 CA CA3092114A patent/CA3092114A1/en active Pending
- 2011-11-17 KR KR1020197019623A patent/KR102229650B1/ko active Active
- 2011-11-17 CN CN201180071918.XA patent/CN103619356B/zh active Active
- 2011-11-17 IL IL273838A patent/IL273838B/en unknown
- 2011-11-17 KR KR1020137032241A patent/KR102183273B1/ko active Active
- 2011-11-17 JP JP2014509281A patent/JP6478632B2/ja active Active
-
2013
- 2013-11-04 IL IL229227A patent/IL229227B/en active IP Right Grant
-
2016
- 2016-08-01 JP JP2016151179A patent/JP2016185991A/ja active Pending
-
2017
- 2017-07-18 AU AU2017206179A patent/AU2017206179A1/en not_active Abandoned
-
2018
- 2018-06-06 JP JP2018108772A patent/JP2018135396A/ja not_active Withdrawn
-
2019
- 2019-07-09 AU AU2019204913A patent/AU2019204913A1/en not_active Abandoned
-
2020
- 2020-04-09 JP JP2020070566A patent/JP6884250B2/ja active Active
-
2021
- 2021-04-13 AU AU2021202224A patent/AU2021202224A1/en not_active Abandoned
- 2021-05-11 JP JP2021080358A patent/JP2021113232A/ja active Pending
-
2023
- 2023-05-18 AU AU2023203112A patent/AU2023203112B2/en active Active
-
2024
- 2024-02-02 JP JP2024014898A patent/JP2024032974A/ja active Pending
-
2025
- 2025-09-04 AU AU2025226744A patent/AU2025226744A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505741A5 (enExample) | ||
| US20200392498A1 (en) | Polynucleotide constructs having bioreversible and non-bioreversible groups | |
| JP2015501817A5 (enExample) | ||
| JP2023055874A (ja) | ステープルまたはステッチペプチドに複合された生物活性化合物 | |
| JP2015505839A5 (enExample) | ||
| JP2011006428A5 (enExample) | ||
| WO2023026994A1 (ja) | ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート | |
| JP2010521485A5 (enExample) | ||
| AU2012377385A2 (en) | Poly(acrylate) polymers for in vivo nucleic acid delivery | |
| JP2019514426A5 (enExample) | ||
| WO2008010463A1 (en) | Polymer conjugate of combretastatin | |
| MX2013011674A (es) | Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados. | |
| JP2019508481A5 (enExample) | ||
| CA2523672A1 (en) | Compositions for enhancing transport of molecules into cells | |
| DK2806896T3 (en) | Chitosan covalently bound to small molecule integrin antagonist for targeted delivery | |
| EP3535397A1 (en) | Alpha-v beta-6 integrin ligands and uses thereof | |
| CA2834128A1 (en) | Peptide oligonucleotide conjugates | |
| JP2024532465A5 (enExample) | ||
| US20240269302A1 (en) | Nanoparticle comprising peptide-lipid conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same | |
| JP2009542582A5 (enExample) | ||
| JP2014525939A5 (enExample) | ||
| IL283646B1 (en) | Axon-skipping oligomer complexes for muscular dystrophy | |
| KR20140127234A (ko) | Ｖｌａ-4 발현 세포로의 표적화된 전달을 위한 인테그린 안타고니스트 접합체 | |
| JP2024536360A5 (enExample) | ||
| JP2016516079A5 (enExample) |